Medigus Receives Approval for Commencement of the First Multi-Center MUSE Clinical Study from CFDA in China

OMER, ISRAEL--(Feb 16, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the China Food and Drug Administration, or CFDA, has approved the commencement of the first multi-center MUSE™ Clinical Study in China.
 
Approval to start the multi-center MUSE™ clinical study was received after the CFDA reviewed the ethics committees' approval and agreements were in place with each center. Under Principal Investigator, Yunsheng Yang, Director of Gastroenterology Department Clinical center at 301 Hospital and chairman of Chinese Society of Gastroenterology, The General Hospital of People's Liberation Army in Beijing, the clinical study of approximately 62 patients, will take place at 5 centers across China:
Read more: Medigus Ltd ( MDGS )

Hologic to Acquire Cynosure, Leader in Medical Aesthetics Systems and Technologies, in All-Cash Tender Offer that Combines Two Complementary Businesses

-Expands Hologic's Scientific and Commercial Expertise into Large, Adjacent Medical Device Segment Growing at Double-Digit Rate -
-Accelerates Hologic's Top- and Bottom-Line Growth Rates and is Immediately Accretive to Non-GAAP Earnings per Share -
 
MARLBOROUGH, Mass. and WESTFORD, Mass., Feb. 14, 2017  -- Hologic, Inc. (Nasdaq: HOLX), a leader in women's health, and Cynosure, Inc. (Nasdaq: CYNO), a leader in medical aesthetics systems and technologies, announced today they have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billion and an enterprise value of $1.44 billion net of cash.
Read more: Cynosure Inc ( CYNO )

Transgenomic Announces Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR as Its Mutation Enrichment Platform

Three-Year Renewable Agreement Also Includes Non-Exclusive License to ICP in Canada
New Patent Has Issued Covering ICE COLD-PCR Technology in Canada
 
OMAHA, Neb. --  Transgenomic, Inc. (TBIO) (NASDAQ: TBIO), today announced a licensing agreement with leading Canadian laboratory services provider LifeLabs, which has selected Transgenomic’s ICE COLD-PCR (ICP) technology as its mutation enrichment platform for cancer testing. The three-year, renewable agreement includes a non-exclusive license to the ICP technology in Canada. Separately, Transgenomic also announced issuance of a new Canadian patent for ICP.
Read more: Transgenomic Inc ( TBIO )

Medigus Receives First Purchase Order for MUSE in Italy

OMER, ISRAEL--(Jan 23, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that it received the first purchase order (PO) for the MUSE™ system in Italy from INNOVAMEDICA S.p.A, a privately-owned distributor of minimally invasive medical devices, in accordance with their existing distribution agreement.
 
"Medigus' partnership with INNOVAMEDICA will expand the commercial availability of MUSE to patients in Italy who are seeking a minimally invasive treatment option for GERD," said Chris Rowland, CEO of Medigus. "We are pleased to offer another key market advanced technologies that enhance patient care and outcomes."
Read more: Medigus Ltd ( MDGS )

XTNT Announces Preliminary Fourth Quarter and Full Year 2016 Revenue & Adjusted EBITDA

Record Fourth Quarter 2016 Revenue is estimated to be at least $24.5 million which represents 10.0% year on year growth -- Full Year 2016 Revenue is estimated to be at least $90.0 million which represents 4.1% year on year growth -- Fourth Quarter 2016 Adjusted EBITDA* is estimated to be at least $1.25 million versus a loss of $350,000 in the Fourth Quarter of 2015 -- Full Year 2016 Adjusted EBITDA* is estimated to be at least $2.2 million versus a pro forma loss of $33,000 for the Full Year 2015 -- Reiterated 2017 Revenue Guidance of between $98 million and $102 million -- Reiterated 2017 Adjusted EBITDA* Guidance of between $7.7 million and $9.2 million
 
BELGRADE, Mont., Jan. 11, 2017 -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has pre-announced that its Fourth Quarter 2016 record revenue is estimated to be at least $24.5 million, an increase of at least 10.0% as compared to revenues of $22.3 million reported in the fourth quarter of 2015. For the full year 2016, the Company has estimated that its sales will be at least $90.0 million, an increase of at least 4.1% as compared to pro-forma revenue of $86.5 million for the full year 2015.
Read more: Xtant Medical Holdings ( XTNT )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker